X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (30) 30
oncology (20) 20
middle aged (16) 16
aged (15) 15
female (14) 14
male (14) 14
adult (13) 13
index medicus (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
cancer (10) 10
treatment outcome (10) 10
chemotherapy (9) 9
aged, 80 and over (7) 7
antineoplastic agents - therapeutic use (7) 7
imatinib mesylate (7) 7
neoplasms - drug therapy (7) 7
randomized-trial (7) 7
survival analysis (6) 6
analysis (5) 5
camptothecin - analogs & derivatives (5) 5
carcinoma, non-small-cell lung - drug therapy (5) 5
fluorouracil (5) 5
lung neoplasms - drug therapy (5) 5
medicine, general & internal (5) 5
randomized controlled trials as topic (5) 5
trial (5) 5
adenocarcinoma - drug therapy (4) 4
antineoplastic agents - adverse effects (4) 4
antineoplastic agents - pharmacokinetics (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
benzamides (4) 4
camptothecin - administration & dosage (4) 4
chemotherapy, adjuvant (4) 4
clinical trials (4) 4
expression (4) 4
infusions, intravenous (4) 4
irinotecan (4) 4
neoplasm staging (4) 4
phase-iii trial (4) 4
therapy (4) 4
angiogenesis (3) 3
antimetabolites, antineoplastic - therapeutic use (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
antineoplastic agents - administration & dosage (3) 3
antineoplastic agents - pharmacology (3) 3
breast-cancer (3) 3
care and treatment (3) 3
combination chemotherapy (3) 3
deoxycytidine - analogs & derivatives (3) 3
deoxycytidine - therapeutic use (3) 3
disease progression (3) 3
disease-free survival (3) 3
follow-up studies (3) 3
hematology, oncology and palliative medicine (3) 3
imatinib (3) 3
leucovorin (3) 3
lung neoplasms - pathology (3) 3
mesylate (3) 3
metabolic clearance rate (3) 3
nausea - chemically induced (3) 3
neoplasms - metabolism (3) 3
oxaliplatin (3) 3
pancreatic neoplasms - drug therapy (3) 3
piperazines - pharmacokinetics (3) 3
pyrimidines - pharmacokinetics (3) 3
retrospective studies (3) 3
solid tumors (3) 3
tumors (3) 3
tyrosine kinase inhibitor (3) 3
vomiting - chemically induced (3) 3
1st-line therapy (2) 2
1st-line treatment (2) 2
5-fluorouracil (2) 2
abridged index medicus (2) 2
adenocarcinoma - secondary (2) 2
adenocarcinoma - surgery (2) 2
adolescent (2) 2
angiogenesis inhibitors - pharmacokinetics (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal - pharmacokinetics (2) 2
antibodies, monoclonal, humanized (2) 2
antineoplastic agents - toxicity (2) 2
antitumor-activity (2) 2
apoptosis (2) 2
area under curve (2) 2
breast cancer (2) 2
c-kit (2) 2
camptothecin - adverse effects (2) 2
carcinoma (2) 2
carcinoma, non-small-cell lung - pathology (2) 2
chronic myeloid-leukemia (2) 2
cisplatin (2) 2
clinical-trial (2) 2
combination (2) 2
combined modality therapy (2) 2
comparing cisplatin (2) 2
cooperative-oncology-group (2) 2
diarrhea - chemically induced (2) 2
docetaxel (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2011, Volume 364, Issue 19, pp. 1817 - 1825
In this study, a four-drug combination chemotherapy regimen was associated with objective responses in more than 30% of patients and increased survival by more... 
PHASE-III TRIAL | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | SOLID TUMORS | CLINICAL-TRIALS | IRINOTECAN | OXALIPLATIN | 1ST-LINE THERAPY | COMBINATION | CARCINOMA | COOPERATIVE-ONCOLOGY-GROUP | Leucovorin - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Pancreatic Neoplasms - drug therapy | Deoxycytidine - therapeutic use | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Neoplasm Metastasis - drug therapy | Adult | Camptothecin - administration & dosage | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Camptothecin - analogs & derivatives | Severity of Illness Index | Pancreatic Neoplasms - pathology | Proportional Hazards Models | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Survival Analysis | Quality of Life | Aged | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Chemotherapy, Combination | Usage | Care and treatment | Gemcitabine | Pancreatic cancer | Leucovorin | Comparative analysis | Drug therapy | Fluorouracil | Clinical trials | Cytotoxicity | Pancreas | Patients | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2007, Volume 25, Issue 9, pp. 1107 - 1113
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2008, Volume 14, Issue 21, pp. 7102 - 7109
Journal Article
Oncology, ISSN 0030-2414, 08/2011, Volume 80, Issue 5-6, pp. 301 - 306
Journal Article
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 10/2018, Volume 105, Issue 10, pp. 862 - 872
Introduction: De nouvelles formes galéniques de trastuzumab et rituximab ont été développées pour administration par voie sous-cutanée, permettant ainsi des... 
Subcutaneous route | Health economics | Rituximab | Monoclonal Antibodies | Trastuzumab
Journal Article
JAMA, ISSN 0098-7484, 05/2010, Volume 303, Issue 17, pp. 1729 - 1737
Journal Article
Journal Article
Therapie, ISSN 0040-5957, 2007, Volume 62, Issue 2, pp. 87 - 90
Journal Article
Bulletin du cancer, 10/2018, Volume 105, Issue 10, p. 862
New pharmaceutical forms of trastuzumab and rituximab which can be administered by the subcutaneous route have been developed recently. For day hospitalisation... 
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2012, Volume 49, Issue 7, pp. 1565 - 1577
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2008, Volume 26, Issue 1, pp. 35 - 43
This study assessed the safety, immunogenicity, and pharmacokinetics of etaracizumab, a monoclonal antibody directed against the αvβ3 integrin, in patients... 
Angiogenesis | Medicine & Public Health | α v β 3 receptor | Endothelial cell adhesion | Advanced solid tumors | Vitaxin | Oncology | Pharmacology/Toxicology | MEDI-522 | receptor
Journal Article